Why Insmed Incorporated (INSM) stock moved
Insmed Incorporated (INSM) shares climbed 15.1% to $111.59 as of October 29, 2026, a sharp gain from the prior close of $96.98. BestStocks flagged the session as a major change for INSM. The move is tied to an earnings miss. Below, we break down what changed for INSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Miss
Insmed Incorporated (INSM) reported EPS of −$0.46 vs. consensus estimate of −$0.38 for Q3 FY2026 on October 29, 2026, missing consensus by 20.1%. Monitor for fourth-quarter guidance or any updates on clinical trial progress or revenue-generating milestones.
What it means for Insmed Incorporated investors
For Insmed Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Strong 15.1% price move with conviction; Volume 4.1x average — institutional conviction. Weighing against that: Earnings missed expectations; Insmed Incorporated (INSM) moved -5.60% from $115.61 to $109.14 on 2026-07-13. Wall Street's consensus price target sits at $191.31, implying +71.4% upside from $111.59. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality high (90/100). With earnings roughly 119 days out, the next report is the most likely near-term test of the move.
INSM price reaction
INSM last traded at $111.59, up $14.61 (+15.06%) from the previous close of $96.98. The session traded on 4.1× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $93.33 and $117.67, and it currently sits about 75% of the way up that band.
Bullish and bearish analyst opinions on Insmed Incorporated (INSM)
The consensus analyst price target on Insmed Incorporated (INSM) is $191.31, 71.4% above the recent $111.59. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 1 downgrade. Here is how the bullish and bearish cases on INSM line up.
The bullish case
- Wall Street's consensus price target of $191.31 implies +71.4% upside from $111.59.
- The Street's most bullish target is $235.00 (+110.6%).
- Strong 15.1% price move with conviction.
- Volume 4.1x average — institutional conviction.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently Wolfe Research to Peer Perform (2026-10-12).
- Earnings missed expectations.
- Insmed Incorporated (INSM) moved -5.60% from $115.61 to $109.14 on 2026-07-13.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for INSM
In-depth INSM event analyses
Frequently asked questions about INSM
Why did Insmed Incorporated (INSM) stock move?
INSM climbed 15.1% to $111.59. The move is associated with an earnings miss.
How much did INSM stock rise?
INSM gained 15.06% ($14.61) versus the prior close of $96.98, last trading at $111.59 on 4.1× average volume.
When is Insmed Incorporated's next earnings date?
INSM's next earnings report is estimated for 2027-02-25 — about 119 days away.
What is the analyst price target for INSM?
The consensus analyst price target for INSM is $191.31, about 71.4% above the current $111.59. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 1 downgrade.
How BestStocks tracks INSM
This page is generated automatically by BestStocks' change-detection system after an earnings miss was detected and verified against independent data sources. It draws on 20 tracked change events for INSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.